Literature DB >> 19369353

Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 4 targets MDM2 to deregulate the p53 tumor suppressor pathway.

Hye-Ra Lee1, Zsolt Toth, Young C Shin, Jong-Soo Lee, Heesoon Chang, Wei Gu, Tae-Kwang Oh, Myung Hee Kim, Jae U Jung.   

Abstract

Cells infected by viruses utilize interferon (IFN)-mediated and p53-mediated irreversible cell cycle arrest and apoptosis as part of the overall host surveillance mechanism to ultimately block viral replication and dissemination. Viruses, in turn, have evolved elaborate mechanisms to subvert IFN- and p53-mediated host innate immune responses. Kaposi's sarcoma-associated herpesvirus (KSHV) encodes several viral IFN regulatory factors (vIRF1 to vIRF4) within a cluster of loci, their functions being primarily to inhibit host IFN-mediated innate immunity and deregulate p53-mediated cell growth control. Despite its significant homology and similar genomic location to other vIRFs, vIRF4 is distinctive, as it does not target and antagonize host IFN-mediated signal transduction. Here, we show that KSHV vIRF4 interacts with the murine double minute 2 (MDM2) E3 ubiquitin ligase, leading to the reduction of p53, a tumor suppressor, via proteasome-mediated degradation. The central region of vIRF4 is required for its interaction with MDM2, which led to the suppression of MDM2 autoubiquitination and, thereby, a dramatic increase in MDM2 stability. Consequently, vIRF4 expression markedly enhanced p53 ubiquitination and degradation, effectively suppressing p53-mediated apoptosis. These results indicate that KSHV vIRF4 targets and stabilizes the MDM2 E3 ubiquitin ligase to facilitate the proteasome-mediated degradation of p53, perhaps to circumvent host growth surveillance and facilitate viral replication in infected cells. Taken together, the indications are that the downregulation of p53-mediated cell growth control is a common characteristic of the four KSHV vIRFs and that p53 is indeed a key factor in the host's immune surveillance program against viral infections.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19369353      PMCID: PMC2698538          DOI: 10.1128/JVI.02353-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  SUMO-1 modification of Mdm2 prevents its self-ubiquitination and increases Mdm2 ability to ubiquitinate p53.

Authors:  T Buschmann; S Y Fuchs; C G Lee; Z Q Pan; Z Ronai
Journal:  Cell       Date:  2000-06-23       Impact factor: 41.582

2.  Viral interferon regulatory factor 1 of Kaposi's sarcoma-associated herpesvirus binds to p53 and represses p53-dependent transcription and apoptosis.

Authors:  T Seo; J Park; D Lee; S G Hwang; J Choe
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

3.  HHV-8 encoded vIRF-1 represses the interferon antiviral response by blocking IRF-3 recruitment of the CBP/p300 coactivators.

Authors:  R Lin; P Genin; Y Mamane; M Sgarbanti; A Battistini; W J Harrington; G N Barber; J Hiscott
Journal:  Oncogene       Date:  2001-02-15       Impact factor: 9.867

4.  The MDM2 RING-finger domain is required to promote p53 nuclear export.

Authors:  R K Geyer; Z K Yu; C G Maki
Journal:  Nat Cell Biol       Date:  2000-09       Impact factor: 28.824

Review 5.  The p53-Mdm2 module and the ubiquitin system.

Authors:  Dan Michael; Moshe Oren
Journal:  Semin Cancer Biol       Date:  2003-02       Impact factor: 15.707

Review 6.  Molecular virology of Kaposi's sarcoma-associated herpesvirus.

Authors:  P S Moore; Y Chang
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

Review 7.  The p53 pathway.

Authors:  C Prives; P A Hall
Journal:  J Pathol       Date:  1999-01       Impact factor: 7.996

8.  Kaposi's sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53.

Authors:  C Rivas; A E Thlick; C Parravicini; P S Moore; Y Chang
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

9.  Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase.

Authors:  R Honda; H Yasuda
Journal:  Oncogene       Date:  2000-03-09       Impact factor: 9.867

Review 10.  Modelling the molecular circuitry of cancer.

Authors:  William C Hahn; Robert A Weinberg
Journal:  Nat Rev Cancer       Date:  2002-05       Impact factor: 60.716

View more
  45 in total

1.  Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 4 (vIRF4/K10) is a novel interaction partner of CSL/CBF1, the major downstream effector of Notch signaling.

Authors:  Katharina Heinzelmann; Barbara A Scholz; Agnes Nowak; Even Fossum; Elisabeth Kremmer; Juergen Haas; Ronald Frank; Bettina Kempkes
Journal:  J Virol       Date:  2010-09-22       Impact factor: 5.103

Review 2.  Molecular biology of human herpesvirus 8: novel functions and virus-host interactions implicated in viral pathogenesis and replication.

Authors:  Emily Cousins; John Nicholas
Journal:  Recent Results Cancer Res       Date:  2014

3.  MDM2 gene polymorphisms and risk of classic Kaposi's sarcoma among Iranian patients.

Authors:  Sajad Varmazyar; Sayed Mahdi Marashi; Zabihollah Shoja; Maria Lina Tornesello; Franco M Buonaguro; Shohreh Shahmahmoodi; Zahra Safaie-Naraghi; Somayeh Jalilvand
Journal:  Med Microbiol Immunol       Date:  2017-01-12       Impact factor: 3.402

4.  A Rhesus Rhadinovirus Viral Interferon (IFN) Regulatory Factor Is Virion Associated and Inhibits the Early IFN Antiviral Response.

Authors:  Gabriela Morin; Bridget A Robinson; Kelsey S Rogers; Scott W Wong
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

5.  KSHV-encoded viral interferon regulatory factor 4 (vIRF4) interacts with IRF7 and inhibits interferon alpha production.

Authors:  Sung-Woo Hwang; DongIk Kim; Jae U Jung; Hye-Ra Lee
Journal:  Biochem Biophys Res Commun       Date:  2017-03-22       Impact factor: 3.575

Review 6.  Multicentric Castleman disease: Where are we now?

Authors:  Hao-Wei Wang; Stefania Pittaluga; Elaine S Jaffe
Journal:  Semin Diagn Pathol       Date:  2016-05-16       Impact factor: 3.464

7.  Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 4 (vIRF4) targets expression of cellular IRF4 and the Myc gene to facilitate lytic replication.

Authors:  Hye-Ra Lee; Sultan Doğanay; Brian Chung; Zsolt Toth; Kevin Brulois; Stacy Lee; Zhansaya Kanketayeva; Pinghui Feng; Taekjip Ha; Jae U Jung
Journal:  J Virol       Date:  2013-12-11       Impact factor: 5.103

8.  The functional MDM2 T309G genetic variant but not P53 Arg72Pro polymorphism is associated with risk of sarcomas: a meta-analysis.

Authors:  Xu Cai; Ming Yang
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-29       Impact factor: 4.553

9.  Kaposi's Sarcoma-Associated Herpesvirus LANA Modulates the Stability of the E3 Ubiquitin Ligase RLIM.

Authors:  Hagar Tadmor; Melanie Greenway; Anuj Ahuja; Ola Orgil; Gangling Liao; Richard F Ambinder; S Diane Hayward; Meir Shamay
Journal:  J Virol       Date:  2020-02-14       Impact factor: 5.103

Review 10.  Viral interferon regulatory factors.

Authors:  Hye-Ra Lee; Myung Hee Kim; Jong-Soo Lee; Chengyu Liang; Jae U Jung
Journal:  J Interferon Cytokine Res       Date:  2009-09       Impact factor: 2.607

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.